G1 Therapeutics Provides Corporate Update at the 42nd Annual

- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate Sacituzumab Govitecan Suggest a Potentially Meaningful Improvement in Overall Survival for Patients...

Related Keywords

, Jack Bailey , Exchange Commission , Linkedin , Therapeutics Inc , Corporate Communications , Research Triangle Park , Nasdaq , Ongoing Phase , Antibody Drug Conjugate , Sacituzumab Govitecan , Potentially Meaningful Improvement , Overall Survival , Patients Receiving Trilaciclib , Vial Volume Growth Accelerated , Fourth Quarter , Growth Over Prior Quarter , Triple Negative Breast Cancer , First Quarter , Runway Expected , Healthcare Conference , Chief Executive Officer , Private Securities Litigation Reform Act , Investor Relations , Markets ,